NEW YORK (GenomeWeb) ― Researchers from Sanofi recently reported preclinical data showing that Regulus Therapeutics' microRNA-21 inhibitor RG-012 can have a therapeutic benefit even in the late stages of Alport syndrome and that it can enhance the effect of the kidney protectant ramipril.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.